UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
Health-related Quality of Life and Patient-reported Outcomes in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol
Completed
- Conditions
- First Posted Date
- 2012-02-03
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 81
- Registration Number
- NCT01526434
- Locations
- 🇪🇸
11, A Coruña, Spain
🇪🇸15, Barcelona, Spain
🇪🇸7, Barcelona, Spain
Effect of Lacosamide 200 mg Twice a Day (Bid) on Single Dose Warfarin 25 mg in Healthy Males
- First Posted Date
- 2012-02-03
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 16
- Registration Number
- NCT01526083
- Locations
- 🇳🇱
001, Zuidlaren, Netherlands
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 359
- Registration Number
- NCT01521923
- Locations
- 🇺🇸
207, Albuquerque, New Mexico, United States
🇺🇸189, Charleston, South Carolina, United States
🇺🇸167, Duncansville, Pennsylvania, United States
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 880
- Registration Number
- NCT01519791
- Locations
- 🇺🇸
159, Los Angeles, California, United States
🇺🇸178, Corpus Christi, Texas, United States
🇺🇸223, Houston, Texas, United States
Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2014-03-03
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 1
- Registration Number
- NCT01519882
- Locations
- 🇬🇧
1, Middlesborough, United Kingdom
Non-interventional, Retrospective, Multi-center Study to Evaluate Non-motor Symptoms in Advanced Parkinson Disease (PD) Patients Already Treated With Rotigotine
Completed
- Conditions
- First Posted Date
- 2012-01-05
- Last Posted Date
- 2013-04-15
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 391
- Registration Number
- NCT01504529
- Locations
- 🇪🇸
45, Barcelona, Spain
🇪🇸52, Barcelona, Spain
🇪🇸14, Avilés, Spain
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 915
- Registration Number
- NCT01500278
- Locations
- 🇺🇸
166, Houston, Texas, United States
🇧🇬35, Plovdiv, Bulgaria
🇵🇹14, Ponte De Lima, Portugal
Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 30
- Registration Number
- NCT01491113
- Locations
- 🇯🇵
2, Ibaraki, Japan
🇯🇵1, Fukuoka, Japan
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 120
- Registration Number
- NCT01484977
- Locations
- 🇺🇸
001, Fresno, California, United States
🇧🇬036, Ruse, Bulgaria
🇫🇷046, Paris, France
To Evaluate the Pharmacokinetics and Safety/Tolerability of Lacosamide in 3 Dosages in Healthy Male Korean Subjects
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2011-10-14
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 51
- Registration Number
- NCT01450111
© Copyright 2024. All Rights Reserved by MedPath